Role of insulin-regulated aminopeptidase as potential biomarker in insulin resistant polycystic ovary syndrome patients.

OBJECTIVE

To measure serum insulin-regulated aminopeptidase levels in women diagnosed with polycystic ovary syndrome and to investigate their potential contribution of these levels to the development of insulin resistance, which plays a central role in the pathophysiology of polycystic ovary syndrome.

METHODS

The study group, recruited between May and December 2021, consisted of 40 patients diagnosed with polycystic ovary syndrome and 40 age-matched healthy controls. Serum insulin-regulated aminopeptidase levels were compared between the groups using the ELISA method.

RESULTS

Serum insulin-regulated aminopeptidase levels were significantly lower in the polycystic ovary syndrome group compared with the control group (p < 0.001). Subparameter assessments revealed that insulin-regulated aminopeptidase levels were even lower in insulin-resistant polycystic ovary syndrome patients (p = 0.001). Moreover, insulin-regulated aminopeptidase levels demonstrated a statistically significant negative correlation with fasting blood glucose, insulin, glycated hemoglobin, and HOMA-IR values.

CONCLUSION

Serum insulin-regulated aminopeptidase levels were found to be lower in women with polycystic ovary syndrome than those in healthy controls. Furthermore, these levels appear to reflect insulin resistance, a key factor in the pathogenesis of polycystic ovary syndrome. Overall, these findings suggest that insulin-regulated aminopeptidase may serve as a potential biomarker for the identifification of insulin resistance in women with polycystic ovary syndrome.